SCHEMBL351856

SCHEMBL351856

Cc1ccc(C(N)=O)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 4/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
HDAC1 Q13547 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
KDM4E B2RXH2 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
F7 P08709 1/20 0.50
F3 P13726 1/20 0.50
SARM1 Q6SZW1 1/20 0.50
SIRT2 Q8IXJ6 1/20 0.50
SIRT6 Q8N6T7 1/20 0.50
SIRT1 Q96EB6 1/20 0.50
SIRT3 Q9NTG7 1/20 0.50
SIRT5 Q9NXA8 1/20 0.50
SIRT4 Q9Y6E7 1/20 0.50
GABRA1 P14867 1/20 0.49
MKNK1 Q9BUB5 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30231615 1.00 NNMT (0.61) NNMTSMN1; SMN2HDAC1HDAC6KDM4E
SCHEMBL28201656 0.89 NNMT (0.50) NNMTSMN1; SMN2HDAC1HDAC6KDM4E
SCHEMBL28176950 0.89 NNMT (0.50) NNMTSMN1; SMN2HDAC1HDAC6KDM4E
SCHEMBL30303086 0.86 HDAC1 (0.55) NNMTSMN1; SMN2HDAC1HDAC6KDM4E
SCHEMBL4400941 0.82 HDAC1 (0.64) SMN1; SMN2HDAC1HDAC6KDM4ELMNA
SCHEMBL575041 0.80 HDAC1 (0.62) HDAC1HDAC6KDM4EL3MBTL1LMNA
SCHEMBL181465 0.80 HDAC1 (0.62) SMN1; SMN2HDAC1HDAC6KDM4EGABRA1
SCHEMBL30544993 0.80 HDAC1 (0.62) SMN1; SMN2HDAC1HDAC6KDM4EGABRA1
SCHEMBL31290288 0.80 HDAC1 (0.62) HDAC1HDAC6KDM4EL3MBTL1LMNA
SCHEMBL17033581 0.78 HDAC1 (0.50) NNMTSMN1; SMN2HDAC1HDAC6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094660-A Composition in the form of an oil-in-water emulsion 2026-05-26 CN claimed
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 US claimed
WO-2025091239-A1 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
WO-2025091220-A2 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
EP-4543408-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'OREAL (FR) 2025-04-30 EP claimed
WO-2025055212-A1 MWW-TYPE MOLECULAR SIEVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国石油化工股份有限公司 2025-03-20 WO claimed
CN-119654151-A Composition for caring skin 莱雅公司 2025-03-18 CN claimed
EP-0896522-B1 METHODS OF REGULATING SKIN APPEARANCE WITH VITAMIN B 3 COMPOUND PROCTER & GAMBLE (US) 2003-10-22 EP claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
WO-2002069916-A2 ANHYDROUS ANTIPERSPIRANT AND DEODORANT COMPOSITIONS CONTAINING A SOLID, WATER-SOLUBLE, SKIN ACTIVE AGENT THE PROCTER & GAMBLE COMPANY (US) 2002-09-12 WO claimed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO claimed
US-6383476-B1 Anhydrous antiperspirant and deodorant compositions containing a solid, water-soluble, skin active agent THE PROCTER & GAMBLE COMPANY 2002-05-07 US claimed
WO-2001078648-A2 6-METHYLNICOTINAMIDE DERIVATIVES AS ANTIVIRAL AGENTS DONG WHA PHARM. IND. CO., LTD. (KR) 2001-10-25 WO claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 NNMT 4154/4885SMN1; SMN2 4266/4885HDAC1 3031/4885
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 NNMT 217/4885SMN1; SMN2 2297/4885HDAC1 3263/4885
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT NNMT 3/4885SMN1; SMN2 1842/4885HDAC1 1037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.